{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:11:21Z","timestamp":1779804681638,"version":"3.53.1"},"posted":{"date-parts":[[2026,5,26]]},"group-title":"In Review","reference-count":26,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,5,9]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  Background\n Vaso-occlusive crises (VOC) are the most frequent complications among people living with sickle cell disease. VOC lead to frequent hospitalisations, reduce quality of life and contribute to long-term sequelae such as stroke, acute chest syndrome, and renal impairment. There are limited contemporary data on the incidence and risk factors for VOC among children with sickle cell anaemia (SCA) after the introduction of hydroxyurea in Uganda.\nMethods\n A prospective cohort study conducted among children living with SCA enrolled in the Uganda Sickle Pan-African Research Consortium Registry, at the Mulago Hospital Sickle Cell Clinic. Participants aged 6 months to 18 years enrolled and followed for six months to assess the occurrence of VOC. Cox proportional hazards regression was used to evaluate associations between clinical and laboratory variables and time to VOC.\nResults\n A total of 438 participants were enrolled, with a median age of 9 years (IQR: 5\u201313). Most participants (80.1%) reported hydroxyurea use. The mean baseline haemoglobin concentration was 7.7 g\/dL (SD: 1.2), and the median foetal haemoglobin (HbF) level was 12.3% (IQR: 7.2\u201318.2). in the preceding year, history of VOC was reported by 88.8%, and 30.1% had received at least one blood transfusion. The incidence of VOC was 102.3 (95% CI: 88.2\u2013118.8) per 100 person-years, with 13% experiencing more than one episode during follow-up. After adjusting for sex and prior VOC history, previous blood transfusion was independently associated with increased VOC risk (aHR: 1.11; 95% CI: 1.02\u20131.22;\n                  <italic>p<\/italic>\n                  \u2009=\u20090.020).\nConclusion\n VOC remains a common and clinically significant complication among Ugandan children living with SCA. Prior blood transfusion was identified as a potential predictor of VOC, underscoring the need for optimised clinical management, including timely and appropriately dosed hydroxyurea therapy, to mitigate risk in this population.\n                <\/p>","DOI":"10.21203\/rs.3.rs-9665061\/v1","type":"posted-content","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T13:28:22Z","timestamp":1779802102000},"source":"Crossref","is-referenced-by-count":0,"title":["Incidence and risk factors for vaso occlusive crisis among children living with sickle cell disease in Uganda: a cohort study"],"prefix":"10.21203","author":[{"given":"Robert","family":"Kitenge","sequence":"first","affiliation":[{"name":"Makerere University College of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Rujumba","sequence":"additional","affiliation":[{"name":"Makerere University College of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"kikaire","sequence":"additional","affiliation":[{"name":"Makerere University College of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deogratias","family":"Munube","sequence":"additional","affiliation":[{"name":"Mulago National Referral Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kiguli","sequence":"additional","affiliation":[{"name":"Makerere University College of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Namazzi","sequence":"additional","affiliation":[{"name":"Makerere University College of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510865","author":"Piel FB","year":"2017","unstructured":"Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. Longo DL, editor. N Engl J Med [Internet]. 2017 Apr 20 [cited 2025 Dec 17];376(16):1561\u201373. Available from: http:\/\/www.nejm.org\/doi\/10.1056\/NEJMra1510865"},{"key":"ref2","author":"Piel FB","year":"2013","unstructured":"Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global Burden of Sickle Cell Anaemia in Children under Five, 2010\u20132050: Modelling Based on Demographics, Excess Mortality, and Interventions. PLoS Med [Internet]. 2013 Jul 16 [cited 2023 Aug 29];10(7):e1001484. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3712914\/"},{"key":"ref3","unstructured":"WORLD HEALTH ORGANIZATION ORGANISATION MONDIALE DE LA SANTE [Internet]. [cited 2025 Dec 17]. Available from: https:\/\/www.afro.who.int\/sites\/default\/files\/2017-06\/afr_rc60_8.pdf"},{"issue":"1","key":"ref4","first-page":"1","article-title":"Sickle cell disease","volume":"4","author":"Kato GJ","year":"2018","unstructured":"Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, et al. Sickle cell disease. Nat reviews Disease primers. 2018;4(1):1\u201322.","journal-title":"Nat reviews Disease primers"},{"key":"ref5","author":"Grosse SD","unstructured":"Grosse SD, Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN. Sickle Cell Disease in Africa. American Journal of Preventive Medicine [Internet]. 2011 Dec [cited 2020 Jul 24];41(6):S398\u2013405. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S074937971100626X"},{"key":"ref6","author":"Ranque B","unstructured":"Ranque B, Kitenge R, Ndiaye DD, Ba MD, Adjoumani L, Traore H et al. Estimating the risk of child mortality attributable to sickle cell anaemia in sub-Saharan Africa: a retrospective, multicentre, case-control study. The Lancet Haematology [Internet]. 2022 Mar [cited 2023 May 21];9(3):e208\u201316. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352302622000047"},{"key":"ref7","author":"McGann PT","unstructured":"McGann PT. Sickle Cell Anemia: An Underappreciated and Unaddressed Contributor to Global Childhood Mortality. The Journal of Pediatrics [Internet]. 2014 Jul [cited 2020 Jul 24];165(1):18\u201322. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022347614001103"},{"key":"ref8","author":"Ndeezi G","unstructured":"Ndeezi G, Kiyaga C, Hernandez AG, Munube D, Howard TA, Ssewanyana I et al. Burden of sickle cell trait and disease in the Uganda Sickle Surveillance Study (US3): a cross-sectional study. The Lancet Global Health [Internet]. 2016 Mar [cited 2023 Feb 15];4(3):e195\u2013200. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214109X15002880"},{"key":"ref9","author":"Rees DC","year":"2010","unstructured":"Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. The Lancet [Internet]. 2010 Dec 11 [cited 2025 Dec 17];376(9757):2018\u201331. Available from: https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(10)61029-X\/abstract"},{"key":"ref10","doi-asserted-by":"publisher","author":"Darbari DS","unstructured":"Darbari DS, Sheehan VA, Ballas SK. The vaso-occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management. Eur J Haematol [Internet]. 2020 Sep [cited 2023 Aug 29];105(3):237\u201346. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13430","DOI":"10.1111\/ejh.13430"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-24762-5","author":"Al-Salem A","year":"2016","unstructured":"Al-Salem A. Medical and Surgical Complications of Sickle Cell Anemia [Internet]. Cham: Springer International Publishing; 2016 [cited 2024 Mar 22]. Available from: http:\/\/link.springer.com\/10.1007\/978-3-319-24762-5"},{"key":"ref12","author":"Shah N","unstructured":"Shah N, Bhor M, Xie L, Arcona S, Halloway R, Paulose J et al. Evaluation of Vaso-occlusive Crises in United States Sickle Cell Disease Patients: A Retrospective Claims-based Study. J Health Econ Outcomes Res [Internet]. [cited 2023 Aug 29];6(3):106\u201317. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7299444\/"},{"key":"ref13","doi-asserted-by":"publisher","author":"Garc\u00eda-Morin M","unstructured":"Garc\u00eda-Morin M, L\u00f3pez-Sang\u00fcos C, V\u00e1zquez P, Alv\u00e1rez T, Mara\u00f1\u00f3n R, Huerta J et al. Lactate Dehydrogenase: A Marker of the Severity of Vaso-Occlusive Crisis in Children with Sickle Cell Disease Presenting at the Emergency Department. Hemoglobin [Internet]. 2016 Nov [cited 2023 Sep 14];40(6):388\u201391. Available from: https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03630269.2016.1275677","DOI":"10.1080\/03630269.2016.1275677"},{"key":"ref14","doi-asserted-by":"publisher","author":"Donaldson A","unstructured":"Donaldson A, Thomas P, Serjeant BE, Serjeant GR. Foetal haemoglobin in homozygous sickle cell disease: a study of patients with low HBF levels *: Low HbF and sickle cell disease. Clinical & Laboratory Haematology [Internet]. 2001 Oct [cited 2023 Dec 14];23(5):285\u20139. Available from: http:\/\/doi.wiley.com\/10.1046\/j.1365-2257.2001.00412.x","DOI":"10.1046\/j.1365-2257.2001.00412.x"},{"key":"ref15","author":"Inusa BPD","unstructured":"Inusa BPD, Hsu LL, Kohli N, Patel A, Ominu-Evbota K, Anie KA et al. Sickle Cell Disease\u2014Genetics, Pathophysiology, Clinical Presentation and Treatment. Int J Neonatal Screen [Internet]. 2019 May 7 [cited 2025 Dec 17];5(2):20. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7510211\/"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1813598","article-title":"Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa","volume":"380","author":"Tshilolo L","year":"2019","unstructured":"Tshilolo L, Tomlinson G, Williams TN, Santos B, Olupot-Olupot P, Lane A, et al. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa. N Engl J Med. 2019;380(2):121\u201331.","journal-title":"N Engl J Med"},{"key":"ref17","author":"Opoka RO","year":"2017","unstructured":"Opoka RO, Ndugwa CM, Latham TS, Lane A, Hume HA, Kasirye P et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood [Internet]. 2017 Dec 14 [cited 2025 Dec 17];130(24):2585\u201393. Available from: https:\/\/ashpublications.org\/blood\/article\/130\/24\/2585\/36868\/Novel-use-Of-Hydroxyurea-in-an-African-Region-with"},{"key":"ref18","author":"Munube D","year":"2017","unstructured":"Munube D. Stroke among Children with Sickle Cell Anemia in Mulago Hospital, Uganda. Austin Pediatr [Internet]. 2017 May 22 [cited 2023 Feb 11];4(2). Available from: http:\/\/austinpublishinggroup.com\/pediatrics\/fulltext\/ajp-v4-id1055.php"},{"key":"ref19","author":"Namazzi R","unstructured":"Namazzi R, Opoka R, Conroy AL, Datta D, Tagoola A, Bond C et al. Zinc for infection prevention in children with sickle cell anemia: a randomized double-blind placebo-controlled trial. Blood Adv [Internet]. 2023 Feb 8 [cited 2024 Feb 27];7(13):3023\u201331. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10331409\/"},{"key":"ref20","author":"Brandow AM","unstructured":"Brandow AM, Carroll CP, Creary S, Edwards-Elliott R, Glassberg J, Hurley RW et al. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv [Internet]. 2020 Jun 19 [cited 2023 Aug 29];4(12):2656\u2013701. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7322963\/"},{"key":"ref21","author":"Ware RE","year":"2017","unstructured":"Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. The Lancet [Internet]. 2017 Jul 15 [cited 2025 Dec 17];390(10091):311\u201323. Available from: https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(17)30193-9\/abstract"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26063","author":"Osunkwo I","year":"2021","unstructured":"Osunkwo I, Andemariam B, Minniti CP, Inusa BPD, El Rassi F, Francis-Gibson B et al. Impact of sickle cell disease on patients\u02bc daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY). American J Hematol [Internet]. 2021 Apr [cited 2023 Dec 14];96(4):404\u201317. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.26063"},{"key":"ref23","author":"Thompson BW","unstructured":"Thompson BW, Miller ST, Rogers ZR, Rees RC, Ware RE, Waclawiw MA et al. The Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG): Challenges of Study Design. Pediatr Blood Cancer [Internet]. 2010 Feb [cited 2026 Feb 6];54(2):250\u20135. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC2795081\/"},{"key":"ref24","volume-title":"Effect of an Educational Program","author":"Adham NAE","unstructured":"Adham NAE, Said DAE, Awad H. Effect of an Educational Program for Parents of Children with Sickle Cell Anemia."},{"key":"ref25","unstructured":"Role of Sociodemographic and Economic Variables. in Predisposition to Vaso-Occlusive Crisis and Mortality in Patients with SCD: Case Study of Sub-Saharan Africa | IntechOpen [Internet]. [cited 2024 Feb 27]. Available from: https:\/\/www.intechopen.com\/chapters\/82509"},{"key":"ref26","author":"Yousif TYE","unstructured":"Yousif TYE. Impact of Abnormal Leukocyte Count in the Pathophysiology of Sickle Cell Anemia. J Blood Med [Internet]. 2022 Nov 16 [cited 2026 Jan 10];13:673\u20139. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9675987\/"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9665061\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9665061\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T13:28:24Z","timestamp":1779802104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9665061\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":26,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-9665061\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,5,26]]},"subtype":"preprint"}}